Adenomatous polyposis coli-mediated control of β-catenin is essential for both chondrogenic and osteogenic differentiation of skeletal precursors
- Razvan L Miclea†1,
- Marcel Karperien†2Email author,
- Cathy AJ Bosch3,
- Geertje van der Horst4,
- Martin A van der Valk5,
- Tatsuya Kobayashi6,
- Henry M Kronenberg6,
- Georges Rawadi7,
- Pinar Akçakaya3,
- Clemens WGM Löwik8,
- Riccardo Fodde9,
- Jan Maarten Wit1 and
- Els C Robanus-Maandag3
© Miclea et al; licensee BioMed Central Ltd. 2009
Received: 04 December 2008
Accepted: 08 April 2009
Published: 08 April 2009
During skeletogenesis, protein levels of β-catenin in the canonical Wnt signaling pathway determine lineage commitment of skeletal precursor cells to osteoblasts and chondrocytes. Adenomatous polyposis coli (Apc) is a key controller of β-catenin turnover by down-regulating intracellular levels of β-catenin.
To investigate whether Apc is involved in lineage commitment of skeletal precursor cells, we generated conditional knockout mice lacking functional Apc in Col2a1-expressing cells. In contrast to other models in which an oncogenic variant of β-catenin was used, our approach resulted in the accumulation of wild type β-catenin protein due to functional loss of Apc. Conditional homozygous Apc mutant mice died perinatally showing greatly impaired skeletogenesis. All endochondral bones were misshaped and lacked structural integrity. Lack of functional Apc resulted in a pleiotropic skeletal cell phenotype. The majority of the precursor cells lacking Apc failed to differentiate into chondrocytes or osteoblasts. However, skeletal precursor cells in the proximal ribs were able to escape the noxious effect of functional loss of Apc resulting in formation of highly active osteoblasts. Inactivation of Apc in chondrocytes was associated with dedifferentiation of these cells.
Our data indicate that a tight Apc-mediated control of β-catenin levels is essential for differentiation of skeletal precursors as well as for the maintenance of a chondrocytic phenotype in a spatio-temporal regulated manner.
During vertebrate embryogenesis, the axial and appendicular skeleton develop through endochondral bone formation. In this process, mesenchymal cells aggregate to form a chondrocytic template that prefigures the shape of the future bone. At the periphery of this cartilaginous mold, osteoblasts differentiate to form the bone collar. The cartilaginous mold is eventually replaced by bone in a step-wise program. Besides chondrocytes and osteoblasts, the skeleton also contains osteoclasts, which are of haematopoietic origin and play pivotal roles in both cartilage and bone resorption and remodelling [1–3].
Every step in the proliferation, differentiation, maturation, apoptosis, and resorption of both chondrocytes and osteoblasts is characterized by a specific transcriptional guideline . Sox9, a high-mobility-group transcription factor, and Runx2, a Runt domain transcription factor, are both expressed in bi-potential skeletal precursor cells differentiating into either chondrocytes or osteoblasts [5–7]. Sox9 and Runx2 play leading roles in lineage commitment of these precursors: upregulation of Sox9 leads to chondrogenic differentiation , while activation of Runx2 is required for their osteogenic commitment .
Recently, based on mouse models, the canonical Wnt/β-catenin signaling pathway was found to act upstream of Sox9 and Runx2. In this pathway, in the absence of a Wnt signal, cytosolic β-catenin is degraded by the ubiquitination/proteasome system upon its phosphorylation at specific Ser-Thr residues by a destruction complex consisting of scaffold proteins such as Axin1, Axin2 (also known as Conductin) and the adenomatous polyposis coli (APC) tumor suppressor, and two kinases, namely glycogen synthase kinase 3β (GSK3β) and casein-kinase 1α (CK1α). Binding of Wnt to a complex composed of the transmembrane frizzled receptor and low-density lipoprotein receptor-related protein 5 or 6 (LRP5 or 6) co-receptor results in inactivation of the destruction complex and accumulation of cytoplasmic β-catenin. Upon its nuclear translocation, β-catenin acts as transcriptional co-activator in complex with transcription factors of the TCF/LEF family, leading to transcriptional activation of Wnt target genes . In wild type mouse embryos, high levels of β-catenin and activation of canonical Wnt signaling have been found in osteoblastic precursors in developing skull and limb bones . Accumulating evidence suggests that increased levels of canonical Wnt/β-catenin signaling inhibit Sox9 expression and activity, and stimulate Runx2 expression, leading to decreased chondrocyte differentiation and increased osteoblast differentiation, respectively [12–15]. Similar results have been found in transgenic mice with Wnt14 overexpression in Collagen 2a1 (Col2a1)-expressing cells .
It has been also demonstrated that β-catenin is required at an early stage to repress chondrocytic differentiation . Upon conditional inactivation of β-catenin in the limb and head mesenchyme before or during early mesenchymal condensations, Prx1-expressing and Dermo1-expressing skeletal precursors, respectively, differentiate into chondrocytes instead of osteoblasts [11, 15]. Finally, results on both constitutively active and inactivated β-catenin in Osterix (Osx)-, Collagen 1a1 (Col1a1)- or Osteocalcin (Osc)-expressing osteoblasts suggest that Wnt/β-catenin signaling coordinates bone formation by controlling the differentiation and activity of both osteoblasts and osteoclasts in a sequential, stage-specific manner [16, 17].
Little is known about the mechanisms regulating β-catenin activity in skeletal precursors. Through its wide range of specific motifs and domains, APC is involved in multiple cellular processes such as signal transduction, cytoskeletal organization, apoptosis, cell adhesion and motility, cell fate determination, and chromosomal stability . However, biochemical and genetic evidence has been provided showing that APC's main tumor suppressing activity resides in its ability to bind to β-catenin and induce its degradation, thereby acting as a strong negative regulator of the canonical Wnt pathway [19–21].
Familial adenomatous polyposis (FAP) patients heterozygous for an APC mutation frequently develop osteomas and dental anomalies . Heterozygous Apc1638N mutant mice occasionally develop osteomas (R. Fodde, personal communication). Homozygosity for the severely truncated ApcMin and for the more hypomorphic Apc1638N allele in the mouse results in a failure of primitive ectoderm development shortly after implantation, leading to lethality prior to gastrulation [23, 24]. Mutant Apc disturbs the differentiation capacity of mouse embryonic stem (ES) cells in a quantitative and qualitative fashion depending on the dose of β-catenin signaling. Aberrant differentiation capacity of ES cells ranges from a strong differentiation blockade in case of two severely truncated ApcMin alleles, to more specific neuroectodermal, dorsal mesodermal, and endodermal defects (e.g., no differentiation in bone or cartilage) in case of two hypomorphic Apc1638N alleles [25, 26]. Osteoblast-specific loss of Apc in the mouse leads to early onset of dramatically increased bone deposition and to lethality early in life . However, Apc has not yet been linked with a role in the differentiation of skeletal precursor cells.
Here, we report that skeletal precursors of the axial and appendicular skeleton, when exposed to an uncontrolled rise of the β-catenin level due to conditional inactivation of Apc, lose their differentiation capacity to both the chondrogenic and osteogenic lineage. Moreover, conditional Apc mutant ribs show enhanced osteoblast activity, while the mutant nasal septum displays chondrocyte dedifferentiation. These results provide the first genetic evidence that Apc plays a crucial role throughout mouse skeletogenesis by regulating the differentiation of skeletal progenitor cells and maintenance of chondrocytes.
Conditional Apc15loxmice and transgenic Col2a1-Cre mice
Recently, we (ECR-M and RF) generated a novel mouse model carrying a conditional Apc15lox allele where exon 15, encoding the majority of the coding region of Apc, and the polyadenylation signal, is flanked by loxP sites. Mice heterozygous and homozygous for the conditional Apc15lox allele did not show any major abnormalities or susceptibility to tumors. Apc Δ15/+ mice, heterozygous for the Apc Δ15 mutant allele obtained by germline Cre-mediated deletion of exon 15, developed multiple intestinal tumors at an early age similar to Apc Min/+ animals. These results indicate that Cre-mediated recombination of the Apc15lox allele leads to inactivation of the Apc protein and to the constitutive activation of Wnt/β-catenin signaling (Robanus-Maandag et al., in preparation).
Heterozygous Apc15lox/+mice do not show any skeletal defect upon Col2a1-driven Cre expression
Apc15lox/15lox mice were bred with Col2a1-Cre mice to generate conditional heterozygous Col2a1-Cre;Apc15lox/+ mice. Microscopical analysis performed on Col2a1-Cre;Apc15lox/+ and control Apc15lox/+ embryos at various developmental stages (E12.5, E14.5, E16.5) displayed a normal spatio-temporal expression of all chondrogenic and osteogenic markers investigated (data not shown).
Homozygous Col2a1-Cre;Apc15lox/15loxmice die perinatally due to severe defects in skeletogenesis
Loss of functional Apc inhibits differentiation of skeletal precursors
Lack of functional Apc results in accumulation of cytoplasmic β-catenin, which subsequently translocates into the nucleus. This process can be well detected by immunohistochemistry (IHC). To investigate endochondral bone formation in Col2a1-Cre;Apc15lox/15lox embryos, we analyzed vertebra formation at E12.5 and E14.5, and humerus development at E16.5 using IHC for β-catenin in combination with Alcian blue staining, and in situ hybridization (ISH) for several chondrocyte- and osteoblast-specific genes. Strongly elevated levels of β-catenin were seen at all sites of endochondral ossification in the Col2a1-Cre;Apc15lox/15lox embryos at E12.5, E14.5 and E16.5, indicating efficient Col2a1-Cre-mediated Apc inactivation.
At E14.5, chondrocytes in the control vertebrae did not stain positively for β-catenin, displayed an intensely Alcian blue-stained matrix and expressed both early (Sox9, Col2a1) and mature chondrocyte markers, like Indian hedgehog (Ihh) and Collagen 10a1 (Col10a1), indicating a normal progression of endochondral ossification (Fig. 5F–J). Although somite formation was present, mutant vertebrae were heavily crumbled and failed to organize in a cartilaginous anlage. Occasionally Alcian blue-positive clusters of chondrocytes were seen, which lacked detectable β-catenin immunostaining and were positive for chondrogenic marker expression. These cells were probably derived from non-recombined cells due to mosaicism of Cre expression. Surrounding these cartilage islands, mesenchymal-like spindle-shaped cells were observed. Comparable to the defects observed at E12.5, these cells expressed high levels of nuclear β-catenin due to Apc inactivation and lacked not only an Alcian blue-positive matrix but also expression of both chondrogenic and osteogenic markers (Fig. 5F–J; data not shown).
Increased osteoblastogenesis in proximal ribs of Col2a1-Cre;Apc15lox/15loxembryos
Chondrocyte dedifferentiation in the nasal septum of Col2a1-Cre;Apc15lox/15loxembryos
The presence of β-catenin-positive cells in the chondrogenic islands suggested that these cells, due to mosaicism of Cre expression, had initiated normal chondrocyte differentiation before undergoing Apc inactivation. Subsequently, the increased level of β-catenin triggered the loss of expression of the early chondrogenic markers and initiated degradation of the ECM. These observations were indicative of dedifferentiated chondrocytes. Similar observations were made in cartilaginous rudiments at other sites of endochondral bone formation, but the effect was most pronounced in the nasal septum (data not shown).
Conditional homozygous loss of functional Apc severely disrupts mouse skeletogenesis via stabilized β-catenin
According to most of the transgenic mouse studies reported, levels of β-catenin, the effector of the canonical Wnt ligands, need to be downregulated in skeletal precursor cells to enable chondrogenic differentiation, whereas elevated β-catenin levels promote differentiation into osteoblasts [11, 12, 15, 35, 36]. This theory is partly based on observations in heterozygous gain-of-function models in which Cre-mediated recombination results in the expression of oncogenic β-catenin. The cellular mechanisms controlling the biological effects of oncogenic β-catenin in the presence of wild type β-catenin are largely unknown. In addition, there are no reports on the role of Apc in regulation of skeletal precursor differentiation via control of β-catenin in the mouse. Here, we have focused on this important role of the multifunctional protein Apc, binding to and downregulating β-catenin. We have selectively inactivated one or both alleles of Apc in murine Col2a1-expressing cells. Our data indicate that the Col2a1 promoter is suitable for this study, since Cre-mediated recombination starts very early (E9.5) in skeletal precursor cells that have not yet committed to the chondrogenic or the osteogenic lineage, consistent with previous findings in other Col2a1-Cre lines [11, 30].
Conditional heterozygous inactivation of Apc does not result in a detectable level of its target β-catenin as determined by IHC. Moreover, heterozygous Col2a1-Cre-mediated Apc inactivation does not interfere with embryonic skeletal development, postnatal growth or bone acquisition up to 24 months of age, as determined by histological and μCT analysis. Our data imply that the level of Apc protein produced by a single functional Apc allele is sufficient to mediate appropriate β-catenin degradation. This is in agreement with normal body weight, size, and growth of young ApcMin/+ mice .
In marked contrast, conditional inactivation of Apc results in a strongly elevated level of (wild type) β-catenin in skeletal precursors, leading to greatly impaired embryogenesis and perinatal lethality. The significantly reduced size and the vast range of skeletal malformations in these embryos is most likely due to the specific Col2a1-Cre activity in skeletal primordias at a very early embryonic stage starting at E9.5 resulting in massive β-catenin accumulation in the developing endochondral skeleton. Probably several factors, like the open rib cage and the severe malformation, from E14.5 on have led to the perinatal lethality. The loss of the multiple β-catenin-independent functions of the Apc protein might have contributed to the gravity and complexity of the skeletal phenotype observed in Col2a1-Cre;Apc15lox/15lox mice as well . Moreover, since Col2a1 expression is not completely restricted to skeletal tissues during mouse embryogenesis , we can not exclude that the severity of the phenotype might have been partly due to loss of functional Apc in other Col2a1-Cre-expressing cell types.
Apc is crucial for both chondrogenic and osteogenic differentiation of skeletal precursors
Wnt/β-catenin signaling represents a mechanism in mesenchymal precursor cells for selecting between chondrocytic and osteoblastic fates. This key regulating role in lineage commitment has been attributed to β-catenin. Indeed, conditional gain-of-function mutation of β-catenin leads to decreased chondrocyte differentiation in Prx1-expressing and Col2a1-expressing cells [12, 15]. However, corresponding increased osteoblast differentiation has not been observed in these models, instead, a decreased osteoblast marker expression has been seen in case of Prx1-expressing cells, suggesting that activation of β-catenin negatively affects skeletogenesis [12, 15]. In addition, conditional loss-of-function mutation of β-catenin in Prx1-expressing cells leads to increased expression of not only chondrocyte but also early osteoblast markers . These data strongly suggest that β-catenin negatively regulates the differentiation of mesenchymal cells into a common skeletal precursor .
We report here that in the vast majority of endochondral skeletal elements, precursor cells lacking functional Apc express strong nuclear β-catenin staining and fail to differentiate into both chondrogenic and osteogenic lineages. These data are in line with the inability of mouse embryonic stem cells carrying specific bi-allelic Apc mutations to differentiate into bone and cartilage . Our data are also consistent with those based on conditional stabilization of β-catenin in mesenchymal skeletal precursors which had an undifferentiated appearance . This consistency strongly suggests that, notwithstanding the multiple functions of Apc, its β-catenin-controlling role is the most important during skeletogenesis. We conclude that Apc plays a crucial role in differentiation of skeletal precursors in vertebrae and long bones: it enables the differentiation into both skeletal lineages by decreasing the level of β-catenin.
Loss of functional Apc in skeletal precursors of the proximal rib stimulates osteogenesis
Although in the vast majority of the endochondral skeleton both chondrogenic and osteogenic differentiation is inhibited due to loss of functional Apc in skeletal precursors, we find a different phenotype in the proximal ribs. Notwithstanding the cartilaginous structure at E14.5, proximal ribs of Col2a1-Cre;Apc15lox/15lox mutants at E16.5 show abundant bone matrix deposited by osteoblasts, invariably expressing high levels of nuclear β-catenin. Since osteoblasts do not express Col2a1, these cells are most likely derived from Col2a1-expressing skeletal precursors lacking functional Apc. This implies that, in contrast to other skeletal elements, skeletal precursors of the proximal ribs are able to escape from the noxious effects of strongly elevated β-catenin levels on differentiation of precursor cells by an as yet unknown mechanism. Since Ihh expression is normal in the non-recombined neighbouring chondrocytes, we speculate that Ihh may be a prime target for inducing osteoblastogenesis in the recombined precursor cells counteracting the noxious effect of β-catenin.
Despite the evidence of functional osteoclasts, the intensely ossified proximal ribs show a strongly diminished bone marrow cavity, rendering it likely that the increased bone formation is due to osteosclerosis. These observations are in agreement with other data, showing that enhanced canonical Wnt signaling can increase bone mass through stimulation of osteoblast activity rather than inhibition of osteoclast formation and activity [39–41]. Such an osteopetrotic phenotype has only been seen in mice with conditional loss of functional Apc or constitutively active β-catenin in already differentiated osteoblasts, resulting in dramatically increased bone deposition [17, 42].
Functional Apc is required to maintain the chondrocyte phenotype
We have found clear evidence for the occurrence of chondrocyte dedifferentiation due to β-catenin accumulation in the nasal septum. Morphologically characterized chondrocytes, which were nuclear β-catenin-positive, lacked expression of typical chondrocyte markers. Furthermore, they were imbedded in an ECM containing significantly less proteoglycans.
Given the noxious effect of increased β-catenin levels on chondrocyte formation (our data and [12, 15]), these cells most likely have undergone Cre-mediated loss of functional Apc after completion of the initial stages of chondrocyte differentiation. Mouse models with an increased level of β-catenin in Col2a1-expressing cells show accelerated chondrocyte maturation [11, 12]. We have found no indication for this phenomenon, implying that the high level of β-catenin due to loss of Apc does not result in chondrocyte maturation but in chondrocyte dedifferentiation. Our data suggest that accumulated β-catenin triggers this dedifferentiation program not only through inhibition of chondrogenic marker expression but also by enhancing the loss of ECM presumably through stimulation of matrix-degrading enzymes. It has been demonstrated that β-catenin increases expression and activity of a number of enzymes involved in matrix degradation [43–45]. β-Catenin stabilization has been associated with dedifferentiation of articular chondrocytes in vitro upon serial monolayer culture, or treatment with retinoic acid or IL1β . Dedifferentiated chondrocytes have also been observed at other sites of endochondral bone formation in the Col2a1-Cre;Apc15lox/15lox embryos, however, the presence of these cells was most pronounced in the nasal septum. Altogether, our data indicate that Apc is required to suppress β-catenin for maintenance of the chondrocytic phenotype.
We show here for the first time that Apc, by negatively controlling the levels of β-catenin, is a critical regulator of the differentiation of skeletal progenitor cells. Conditional inactivation of the mouse Apc gene results in a heterogeneous skeletal phenotype. Based on our results, we postulate that Apc-mediated control of the dosage of transcriptionally active β-catenin protein is directive for the differentiation program of skeletal precursor cells. In the vast majority of the skeletal precursors, loss of functional Apc leads to a strongly increased β-catenin level, resulting in the formation of an undifferentiated mesenchymal cell, which lacks differentiation potential for both osteogenic and chondrogenic lineages. When the inhibitory effect of a strongly increased β-catenin level in the skeletal precursors is reduced, highly active osteoblasts arise. Strong repression of β-catenin in these precursors is required for chondrogenesis. Support for our hypothesis on the importance of the dosage of Apc and β-catenin is provided by observations in Col2a1-Wnt14 transgenic mice . Higher levels of Wnt14 expression resulting in a high level of β-catenin block differentiation of skeletal precursors into chondrocytes or osteoblasts, whereas lower levels of Wnt14 expression result in enhanced ossification. We provide evidence that Apc plays a crucial role in modulating the β-catenin level during mouse skeletogenesis in a spatio-temporal regulated manner. In skeletal precursor cells, Apc is required for differentiation into both chondrocytes and osteoblasts. In addition, Apc is essential in chondrocytes to maintain their phenotype and enable their maturation.
All animal studies were approved by the ethical committee of the Leiden University Medical Centre and complied with national laws relating to the conduct of animal experiments. The Apc15lox/+ mouse was generated by gene targeting in IB10 embryonic stem cells, using a 22.5 kb targeting vector containing loxP sites flanking the last exon of Apc, i.e. exon 15. LoxP sites were inserted in the BglII site of intron 14 and in the ApaI site approximately 350 bp downstream of the Apc polyadenylation signal. Exon 15 of the Apc gene encodes for codons 660 to 2842 of the Apc protein and harbours all the functional domains of Apc involved in β-catenin regulation as well as the C-terminal domains binding to microtubules, DLG, and EB1. Therefore, following Cre-mediated deletion of exon 15, functionality of the remaining protein will be fully impaired with respect to the main function of Apc, i.e. β-catenin regulating. Moreover, as deletion of exon 15 also removes the polyadenylation signal, no stable mRNA is produced and as a consequence no stable truncated protein will be generated. A full description of this new conditional Apc mouse model is currently in preparation (Robanus-Maandag et al., in preparation). Col2a1-Cre mice  were mated with Apc15lox/15lox mice. Of the offspring, Col2a1-Cre+/-;Apc15lox/+ mice were mated with Apc15lox/15lox mice to obtain Col2a1-Cre+/-;Apc15lox/15lox mice. LacZ reporter mice were obtained from Dr. Xiaohong Mao . Routine mouse genotyping was performed on tail DNAs by PCR (Robanus-Maandag et al., in preparation).
Skeletons of mouse embryos were stained with Alcian blue and Alizarin red for cartilaginous and mineralized tissues, respectively, according to standard procedures . For micro-computed tomography (μCT) analysis, femora were recovered from 12-week-old mice after death and processed as described .
β-galactosidase staining, Histology, Immunohistochemistry, In Situ Hybridization
Whole mount β-galactosidase staining was performed as described , from E16.5 on after removal of the skin. For histology, immunohistochemistry, and in situ hybridization, specimens were fixed in phosphate-buffered formalin, embedded in paraffin, and sectioned at 6 μm. Hematoxylin/eosin, Nuclear red, Toluidine blue, and von Kossa stainings were performed according to standard procedures. For immunohistochemistry, sections were treated with 1% H2O2 in 40% methanol/60% TBS for 30 minutes to reduce endogenous peroxidase activity. For antigen retrieval the sections were boiled in Tris-EDTA pH 9.0 for 20 minutes. Blocking was performed with 5% blocking buffer for 30 minutes at 37°C (Boehringer Ingelheim). Sections were incubated with the primary mouse monoclonal antibody against β-catenin (1:100; BD Transduction Laboratories) overnight at 4°C, followed by incubation with the second antibody biotin-conjugated rabbit anti-mouse IgG (1:300; Amersham Biosciences) for 45 minutes at 37°C. The biotinylated proteins were detected by incubation with horseradish peroxidase-conjugated streptavidin (1:200; Amersham Biosciences) for 30 minutes at 37°C and visualized with DAB (Sigma). After counterstaining with Alcian blue for 15 minutes and hematoxylin for 1 minute, sections were dehydrated and embedded in Histomount (BDH). For in situ hybridization, digoxigenin-labeled single-stranded RNA probes were prepared using a DIG RNA labeling kit (Boehringer) following the manufacturers' instructions. All probes are available upon request. In situ hybridization was carried out as described [15, 50]. Images were taken with a DXM-1200 digital camera (Nikon).
We thank Christine Hartmann (IMP, Vienna, Austria) for the mouse Runx2, Sox9, Osc, and Ihh probes, Eero Vuorio (University of Turku, Finland) for the mouse Col1a1 and Col2a1 probes, and Willy Hofstetter (University of Bern, Switzerland) for the mouse Col10a1 probe.
This work was financially supported by a short-term research fellowship from the European Society for Pediatric Endocrinology (RLM), an unrestricted educational grant from IPSEN FARMACEUTICA BV (RLM), a research grant from The Human Growth Foundation (MK), and a research grant from the Association for International Cancer Research (CAJB).
- Karsenty G: Genetics of skeletogenesis. Dev Genet. 1998, 22: 301-313. 10.1002/(SICI)1520-6408(1998)22:4<301::AID-DVG1>3.0.CO;2-A.View ArticlePubMedGoogle Scholar
- Karsenty G, Wagner EF: Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2002, 2: 389-406. 10.1016/S1534-5807(02)00157-0.View ArticlePubMedGoogle Scholar
- Tuan RS: Biology of developmental and regenerative skeletogenesis. Clin Orthop Relat Res. 2004, S105-S117. 10.1097/01.blo.0000143560.41767.ee.Google Scholar
- Olsen BR, Reginato AM, Wang W: Bone development. Annu Rev Cell Dev Biol. 2000, 16: 191-220. 10.1146/annurev.cellbio.16.1.191.View ArticlePubMedGoogle Scholar
- Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B: The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 2002, 16: 2813-2828. 10.1101/gad.1017802.PubMed CentralView ArticlePubMedGoogle Scholar
- Smith N, Dong Y, Lian JB, Pratap J, Kingsley PD, van Wijnen AJ, Stein JL, Schwarz EM, O'Keefe RJ, Stein GS, et al: Overlapping expression of Runx1(Cbfa2) and Runx2(Cbfa1) transcription factors supports cooperative induction of skeletal development. J Cell Physiol. 2005, 203: 133-143. 10.1002/jcp.20210.View ArticlePubMedGoogle Scholar
- Zhou G, Zheng Q, Engin F, Munivez E, Chen Y, Sebald E, Krakow D, Lee B: Dominance of SOX9 function over RUNX2 during skeletogenesis. Proc Natl Acad Sci USA. 2006, 103: 19004-19009. 10.1073/pnas.0605170103.PubMed CentralView ArticlePubMedGoogle Scholar
- Lefebvre V, Smits P: Transcriptional control of chondrocyte fate and differentiation. Birth Defects Res C Embryo Today. 2005, 75: 200-212. 10.1002/bdrc.20048.View ArticlePubMedGoogle Scholar
- Kobayashi T, Kronenberg H: Minireview: transcriptional regulation in development of bone. Endocrinology. 2005, 146: 1012-1017. 10.1210/en.2004-1343.View ArticlePubMedGoogle Scholar
- Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 2006, 127: 469-480. 10.1016/j.cell.2006.10.018.View ArticlePubMedGoogle Scholar
- Day TF, Guo X, Garrett-Beal L, Yang Y: Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005, 8: 739-750. 10.1016/j.devcel.2005.03.016.View ArticlePubMedGoogle Scholar
- Akiyama H, Lyons JP, Mori-Akiyama Y, Yang X, Zhang R, Zhang Z, Deng JM, Taketo MM, Nakamura T, Behringer RR, et al: Interactions between Sox9 and beta-catenin control chondrocyte differentiation. Genes Dev. 2004, 18: 1072-1087. 10.1101/gad.1171104.PubMed CentralView ArticlePubMedGoogle Scholar
- Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, Javed A, van Wijnen AJ, Stein JL, Stein GS, et al: Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem. 2005, 280: 33132-33140. 10.1074/jbc.M500608200.View ArticlePubMedGoogle Scholar
- Dong YF, Soung DY, Schwarz EM, O'Keefe RJ, Drissi H: Wnt induction of chondrocyte hypertrophy through the Runx2 transcription factor. J Cell Physiol. 2006, 208: 77-86. 10.1002/jcp.20656.View ArticlePubMedGoogle Scholar
- Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C: Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell. 2005, 8: 727-738. 10.1016/j.devcel.2005.02.013.View ArticlePubMedGoogle Scholar
- Rodda SJ, McMahon AP: Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006, 133: 3231-3244. 10.1242/dev.02480.View ArticlePubMedGoogle Scholar
- Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO: Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem. 2005, 280: 21162-21168. 10.1074/jbc.M501900200.View ArticlePubMedGoogle Scholar
- Fodde R: The multiple functions of tumour suppressors: it's all in APC. Nat Cell Biol. 2003, 5: 190-192. 10.1038/ncb0303-190.View ArticlePubMedGoogle Scholar
- Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H: Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science. 1997, 275: 1784-1787. 10.1126/science.275.5307.1784.View ArticlePubMedGoogle Scholar
- Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997, 275: 1787-1790. 10.1126/science.275.5307.1787.View ArticlePubMedGoogle Scholar
- Smits R, Houven van Oordt van der W, Luz A, Zurcher C, Jagmohan-Changur S, Breukel C, Khan PM, Fodde R: Apc1638N: a mouse model for familial adenomatous polyposis-associated desmoid tumors and cutaneous cysts. Gastroenterology. 1998, 114: 275-283. 10.1016/S0016-5085(98)70478-0.View ArticlePubMedGoogle Scholar
- Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P, Pierotti M, Spinelli P, Radice P: Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol. 2003, 21: 1698-1707. 10.1200/JCO.2003.09.118.View ArticlePubMedGoogle Scholar
- Fodde R, Edelmann W, Yang K, van Leeuwen C, Carlson C, Renault B, Breukel C, Alt E, Lipkin M, Khan PM: A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci USA. 1994, 91: 8969-8973. 10.1073/pnas.91.19.8969.PubMed CentralView ArticlePubMedGoogle Scholar
- Moser AR, Shoemaker AR, Connelly CS, Clipson L, Gould KA, Luongo C, Dove WF, Siggers PH, Gardner RL: Homozygosity for the Min allele of Apc results in disruption of mouse development prior to gastrulation. Dev Dyn. 1995, 203: 422-433.View ArticlePubMedGoogle Scholar
- Kielman MF, Rindapaa M, Gaspar C, van Poppel N, Breukel C, van Leeuwen S, Taketo MM, Roberts S, Smits R, Fodde R: Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling. Nat Genet. 2002, 32: 594-605. 10.1038/ng1045.View ArticlePubMedGoogle Scholar
- Fodde R, Smits R: Cancer biology. A matter of dosage. Science. 2002, 298: 761-763. 10.1126/science.1077707.View ArticlePubMedGoogle Scholar
- Schipani E, Ryan HE, Didrickson S, Kobayashi T, Knight M, Johnson RS: Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. Genes Dev. 2001, 15: 2865-2876.PubMed CentralPubMedGoogle Scholar
- Mao X, Fujiwara Y, Orkin SH: Improved reporter strain for monitoring Cre recombinase-mediated DNA excisions in mice. Proc Natl Acad Sci USA. 1999, 96: 5037-5042. 10.1073/pnas.96.9.5037.PubMed CentralView ArticlePubMedGoogle Scholar
- Cheah KS, Lau ET, Au PK, Tam PP: Expression of the mouse alpha 1(II) collagen gene is not restricted to cartilage during development. Development. 1991, 111: 945-953.PubMedGoogle Scholar
- Long F, Chung UI, Ohba S, McMahon J, Kronenberg HM, McMahon AP: Ihh signaling is directly required for the osteoblast lineage in the endochondral skeleton. Development. 2004, 131: 1309-1318. 10.1242/dev.01006.View ArticlePubMedGoogle Scholar
- Christ B, Wilting J: From somites to vertebral column. Ann Anat. 1992, 174: 23-32.View ArticlePubMedGoogle Scholar
- Aoyama H, Mizutani-koseki S, Koseki H: Three developmental compartments involved in rib formation. Int J Dev Biol. 2005, 49: 325-333. 10.1387/ijdb.041932ha.View ArticlePubMedGoogle Scholar
- Wealthall RJ, Herring SW: Endochondral ossification of the mouse nasal septum. Anat Rec A Discov Mol Cell Evol Biol. 2006, 288: 1163-1172.View ArticlePubMedGoogle Scholar
- Roberts GJ, Lucas VS: Growth of the nasal septum in the Snell strain of hypopituitary dwarf mouse. Eur J Orthod. 1994, 16: 138-148.View ArticlePubMedGoogle Scholar
- Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, Long F: Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development. 2005, 132: 49-60. 10.1242/dev.01564.View ArticlePubMedGoogle Scholar
- Tamamura Y, Otani T, Kanatani N, Koyama E, Kitagaki J, Komori T, Yamada Y, Costantini F, Wakisaka S, Pacifici M, et al: Developmental regulation of Wnt/beta-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification. J Biol Chem. 2005, 280: 19185-19195. 10.1074/jbc.M414275200.View ArticlePubMedGoogle Scholar
- Moser AR, Pitot HC, Dove WF: A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 1990, 247: 322-324. 10.1126/science.2296722.View ArticlePubMedGoogle Scholar
- Hartmann C: A Wnt canon orchestrating osteoblastogenesis. Trends Cell Biol. 2006, 16: 151-158. 10.1016/j.tcb.2006.01.001.View ArticlePubMedGoogle Scholar
- Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA, Hartmann C, Li L, Hwang TH, Brayton CF, et al: Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol. 2002, 157: 303-314. 10.1083/jcb.200201089.PubMed CentralView ArticlePubMedGoogle Scholar
- Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, Gaur T, Stein GS, Lian JB, Komm BS: The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol. 2004, 18: 1222-1237. 10.1210/me.2003-0498.View ArticlePubMedGoogle Scholar
- Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, Macdougald OA: Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA. 2005, 102: 3324-3329. 10.1073/pnas.0408742102.PubMed CentralView ArticlePubMedGoogle Scholar
- Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, et al: Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005, 8: 751-764. 10.1016/j.devcel.2005.02.017.View ArticlePubMedGoogle Scholar
- Yuasa T, Otani T, Koike T, Iwamoto M, Enomoto-Iwamoto M: Wnt/beta-catenin signaling stimulates matrix catabolic genes and activity in articular chondrocytes: its possible role in joint degeneration. Lab Invest. 2008, 88: 264-74. 10.1038/labinvest.3700747.View ArticlePubMedGoogle Scholar
- Enomoto-Iwamoto M, Otani T, Koike T, Iwamoto M: Wnt/β-Catenin Signaling in Chondrocyte Function and Cartilage Matrix Disruption. Current rheumatology reviews. 2006, 2: 31-38. 10.2174/157339706775697035.View ArticleGoogle Scholar
- Zhu M, Tang D, Wu Q, Hao S, Chen M, Xie C, Rosier RN, O'Keefe RJ, Zuscik M, Chen D: Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J Bone Miner Res. 2009, 24: 12-21. 10.1359/jbmr.080901.PubMed CentralView ArticlePubMedGoogle Scholar
- Ryu JH, Kim SJ, Kim SH, Oh CD, Hwang SG, Chun CH, Oh SH, Seong JK, Huh TL, Chun JS: Regulation of the chondrocyte phenotype by beta-catenin. Development. 2002, 129: 5541-5550. 10.1242/dev.00110.View ArticlePubMedGoogle Scholar
- McLeod MJ: Differential staining of cartilage and bone in whole mouse fetuses by alcian blue and alizarin red S. Teratology. 1980, 22: 299-301. 10.1002/tera.1420220306.View ArticlePubMedGoogle Scholar
- Clement-Lacroix P, Ai M, Morvan F, Roman-Roman S, Vayssiere B, Belleville C, Estrera K, Warman ML, Baron R, Rawadi G: Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA. 2005, 102: 17406-17411. 10.1073/pnas.0505259102.PubMed CentralView ArticlePubMedGoogle Scholar
- Dannenberg JH, Schuijff L, Dekker M, van der Valk M, te Riele H: Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev. 2004, 18: 2952-2962. 10.1101/gad.322004.PubMed CentralView ArticlePubMedGoogle Scholar
- Eerden van der BC, van Til NP, Brinkmann AO, Lowik CW, Wit JM, Karperien M: Gender differences in expression of androgen receptor in tibial growth plate and metaphyseal bone of the rat. Bone. 2002, 30: 891-896. 10.1016/S8756-3282(02)00723-8.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.